Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
  • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
  • C07D513/14—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents

Definitions

• the present invention relates to new thiazolo [3.2-a] quinoline derivatives, processes for their preparation and antibacterial agents containing them.
• R 1 represents hydrogen or methyl optionally substituted by halogen or methoxy
• R 2 represents hydrogen, optionally substituted by hydroxy, methoxy, amino, methylamino or dimethylamino alkyl having 1 to 4 carbon atoms or (5-methyl-2-oxo-l, 3-dioxol-4-yl) methyl ,
• X represents nitrogen or CR 4 , wherein
• R 4 represents hydrogen, halogen or methoxy or, together with R 1, can form a bridge of the structure -O-CH 2 - or -S-CH 2 -, for the remains of the structures
• , 10 represents hydrogen, optionally substituted by hydroxyl-C 3 alkyl, alkoxycarbonyl having 1 to 4 carbon atoms in the alkoxy part or C ] -C 3 -acyl,
• L 1! represents hydrogen or methyl
• R 9 represents hydrogen, methyl or residues of the structures
• -CH CH-COOR 9 ' , -CH 2 -CH 2 -COOR 9' , -CH 2 -CO-CH 3 , -CH 2 -CH 2 -CN,
• R 9 ' represents methyl or ethyl
• B represents -CH 2 -, O or a direct bond.
• the compounds of the formula (I) can be present in the form of racemates or as enantiomerically pure compounds and in the form of their pharmaceutically usable hydrates and acid addition salts and in the form of their alkali metal, alkaline earth metal, silver and guanidinium salts.
• R 1 , R 2 and X have the meaning given above and
• Y represents fluorine or chlorine
• the compounds according to the invention have a higher antibacterial activity, particularly in the gram-positive range. They are therefore suitable as active ingredients for human and veterinary medicine, whereby veterinary medicine also includes the treatment of fish for therapy or for the prevention of bacterial infections.
• R 2 represents hydrogen, optionally substituted by hydroxy, methoxy, amino, methylamino or dimethylamino alkyl having 1 to 4 carbon atoms or (5-methyl-2-oxo-l, 3-dioxol-4-yl) methyl ,
• X represents nitrogen or CR 4 , wherein
• R 4 represents hydrogen, halogen or methoxy or, together with R 1, can form a bridge of the structure -O-CH 2 - or -S-CH 2 -,
• R 5 represents hydrogen, hydroxy, -NR 10 R ⁇ , hydroxymethyl, -CH 2 -NR 10 R n ,
• R 10 for hydrogen, optionally substituted by hydroxy C ] -C 2 alkyl, alkoxycarbonyl having 1 to 4 carbon atoms in the
• R 11 represents hydrogen or methyl
• R 6 represents hydrogen, straight-chain or branched C ] -C 3 -alkyl or cyclopropyl
• R 7 represents hydrogen or methyl
• R 8 represents hydrogen
• R 9 represents hydrogen or methyl
• B represents -CH 2 -, O or a direct bond
• R 1 represents methyl
• R 2 represents hydrogen, methyl or ethyl
• X represents nitrogen or CR 4 , wherein
• R 4 represents hydrogen, chlorine, fluorine or methoxy or, together with R 1, can form a bridge of the structure -O-CH 2 - or -S-CH 2 -,
• R 5 for hydrogen, hydroxy, -NR 1 ⁇ 0 ⁇ ⁇ R> l n l, hydroxymethyl,
• R 10 represents hydrogen, methyl, alkoxycarbonyl with 1 to 4 C atoms in the alkoxy part or C 1 -C 3 acyl,
• R 11 represents hydrogen or methyl
• R represents hydrogen, straight-chain or branched C j -C j alkyl or cyclopropyl
• R 7 represents hydrogen or methyl
• R 8 represents hydrogen
• R 9 represents hydrogen or methyl
• B represents -CH 2 -, O or a direct bond
• the compounds of the formula (II) used as starting compounds are known or can be prepared by known processes. They can optionally be used as racemates, enantiomers or pure diastereomers
• the amines of the formula (DI) used as starting compounds are known. Chiral amines can be used both as racemates and as enantiomerically or diastereomerically pure compounds.
• Examples include:
• reaction of (II) with (III), in which the compounds (III) can also be used in the form of their salts, such as, for example, the hydrochlorides, is preferably carried out in a diluent such as dimethyl sulfoxide, N, N-dimethylformamide, N-methylpyrrolidone, hexamethyl-phosphoric acid trisamide, sulfolane, acetonitrile, water, an alcohol such as methanol, ethanol, n-propanol, isopropanol, gly- Kolmonomethylether or pyridine made. Mixtures of these diluents can also be used.
• a diluent such as dimethyl sulfoxide, N, N-dimethylformamide, N-methylpyrrolidone, hexamethyl-phosphoric acid trisamide, sulfolane, acetonitrile, water, an alcohol such as methanol, ethanol, n-propanol,
• acid binders can be used as acid binders. These preferably include the alkali metal hydroxides, alkali metal carbonates, organic amines and amidines. The following may be mentioned as particularly suitable: triethylamine, 1,4-diazabicyclo [2.2.2] octane (DABCO), 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU) or excess amine (ID ).
• DABCO 1,4-diazabicyclo [2.2.2] octane
• DBU 1,8-diazabicyclo [5.4.0] undec-7-ene
• ID excess amine
• reaction temperatures can be varied over a wide range. Generally one works between about 20 and 200 ° C, preferably between 80 and 180 ° C.
• the reaction can be carried out at normal pressure, but also at elevated pressure. Generally one works at pressures between 1 bar and 100 bar, preferably between 1 and 10 bar.
• Free amino groups can be protected during the reaction by a suitable amino protecting group, for example by the tert-butoxycarbonyl radical, and can be released again after the reaction has ended by treatment with a suitable acid such as hydrochloric acid or trifluoroacetic acid (see Houben-Weyl, methods of Organic Chemistry, Volume E4, page 144 (1983); JFW Mc Omie, Protective Groups in Organic Chemistry (1973), page 43).
• a suitable amino protecting group for example by the tert-butoxycarbonyl radical
• a suitable acid such as hydrochloric acid or trifluoroacetic acid
• esters according to the invention are reacted with suitable haloalkyl derivatives in a solvent such as dimethylformamide, dimethyl acetamide, N-methylpyrrolidone by reacting an alkali metal salt of the underlying carboxylic acid, which can optionally be protected on the N atom by a protective group such as the tert-butoxycarbonyl radical.
• a solvent such as dimethylformamide, dimethyl acetamide, N-methylpyrrolidone
• an alkali metal salt of the underlying carboxylic acid which can optionally be protected on the N atom by a protective group such as the tert-butoxycarbonyl radical.
• Dimethyl sulfoxide or tetramethyl urea at temperatures of about 0 to 100 ° C, preferably 0 to 50 ° C, obtained.
• the acid addition salts of the compounds according to the invention are prepared in the customary manner, for example by dissolving the betaine in a sufficient amount of aqueous acid and precipitating the salt with a water-miscible one organic solvents such as methanol, ethanol, acetone, acetonitrile. You can also heat equivalent amounts of betaine and acid in water or an alcohol such as glycol monoethyl ether and then evaporate to dryness or vacuum the precipitated salt.
• Examples of pharmaceutically usable salts are the salts of hydrochloric acid, sulfuric acid, acetic acid, glycolic acid,
• Lactic acid succinic acid, citric acid, tartaric acid, methanesulfonic acid, 4-toluenesulfonic acid, galacturonic acid, gluconic acid, embonic acid, glutamic acid or aspartic acid.
• the compounds according to the invention can be bound to acidic or basic ion exchangers.
• the alkali metal or alkaline earth metal salts of the carboxylic acids according to the invention are obtained, for example, by dissolving the betaine in a deficient alkali metal or alkaline earth metal solution, filtering undissolved betaine and evaporating the filtrate to dryness.
• Sodium, potassium or calcium salts are pharmaceutically suitable.
• the corresponding silver salts are obtained by reacting an alkali or alkaline earth metal salt with a suitable silver salt such as silver nitrate.
• the compounds according to the invention have a strong antibiotic effect and, with low toxicity, show a broad antibacterial spectrum against gram-positive and gram-negative germs, in particular also against those which are resistant to various antibiotics, such as e.g. Penicillins, cephalosporins, aminoglycosides, sulfonamides, tetracyclines.
• the compounds according to the invention are active against a very broad spectrum of microorganisms. With their help, gram-negative and gram-positive bacteria and bacterial-like microorganisms can be combated and the diseases caused by these pathogens can be prevented, improved and / or cured.
• the compounds according to the invention are distinguished by an increased action on dormant and resistant germs. With resting bacteria, that is bacteria that show no detectable growth, the compounds act below concentrations of similar substances. This relates not only to the amount to be used, but also to the speed of the kill. Such results have been observed in gram-positive and negative bacteria, particularly Staphylococcus aureus, Micrococcus luteus and Enterococcus faecalis.
• the compounds according to the invention also show surprising increases in activity against bacteria which are classified as less sensitive to comparable substances, in particular resistant Staphylococcus aureus and Enterococcus faecalis.
• the compounds according to the invention are particularly effective against bacteria and bacteria-like microorganisms. They are therefore particularly well suited for the prophylaxis and chemotherapy of local and systemic infections in human and veterinary medicine which are caused by these pathogens.
• the compounds are also suitable for combating protozoonoses and
• the compounds according to the invention can be used in various pharmaceutical preparations. Tablets, dragees, capsules, pills, granules, suppositories, solutions for injection and oral administration, suspensions and emulsions, as well as pastes, ointments, gels, creams, lotions, powders and sprays may be mentioned as preferred pharmaceutical preparations.
• the active substances are particularly suitable for combating bacterial diseases that occur in livestock farming and animal breeding in farm animals, breeding, zoo, laboratory, experimental and hobby animals. They are effective against all or individual stages of development as well as against resistant and normally sensitive strains. By combating bacterial diseases, illness, deaths and reduced performance (e.g. in the production of meat, milk, wool, skins, eggs, honey, etc.) are to be reduced, so that the use of the active ingredients enables more economical and simple animal husbandry.
• the livestock and breeding animals include mammals such as cattle, horses, sheep, pigs, goats, camels, water buffalos, donkeys, rabbits, fallow deer, reindeer, fur animals such as mink, chinchilla, raccoon, birds such as chickens, geese, turkeys, Ducks, pigeons, bird species for home and zoo keeping. It also includes farm and ornamental fish.
• Laboratory and experimental animals include mice, rats, guinea pigs, golden hamsters, dogs and cats.
• the pets include dogs and cats.
• the active ingredients can also be administered together with the animal's feed or drinking water.
• Feed and food contain 0.01 to 100 ppm, preferably 0.5 to 50 ppm of the active ingredient in combination with a suitable edible material.
• Such feed and food can be used for medicinal purposes as well as for prophylactic purposes.
• Such feed or food is produced by mixing a concentrate or a premix containing 0.5 to 30%, preferably 1 to 20% by weight of an active ingredient in admixture with an edible organic or inorganic carrier with conventional feed.
• Edible carriers are e.g. Corn meal or corn and soybean meal or mineral salts, which preferably contain a small amount of an edible dust control oil, e.g. Corn oil or soybean oil.
• the premix obtained in this way can then be added to the complete feed before it is fed to the animals.
• the minimum inhibitory concentrations (MIC) of the compounds according to the invention were determined by serial dilution methods on Iso-Sensitest agar (oxoid). A series of agar plates were prepared for each test substance, the concentrations of the active ingredient decreasing at twice the dilution contained. The agar plates were inoculated with a multipoint inoculator (Denley). Overnight cultures of the pathogens were used for inoculation, which were previously diluted so that each inoculation point contained approximately 10 4 colony-forming particles. The inoculated agar plates were incubated at 37 ° C. and the germ growth was read off after about 20 hours. The MIC value ( ⁇ g ml) indicates the lowest active substance concentration at which no growth was visible to the naked eye.
• Staphylococcus ICB 25701 0.5 0.06 0.06 0.06 aureus ATCC 29213 ⁇ 0.015 ⁇ 0.015 ⁇ 0.015 ⁇ 0.015 ⁇ 0.015
• Example 3 Analogously to Example 1, the title compound is obtained in the reaction with (IS, 6S) -2,8-diazabicyclo- [4.3.0] nonane. Melting point: 270-278 ° C (with decomposition)
• Example 3 Analogously to Example 1, the title compound is obtained in the reaction with (IS, 6S) -2,8-diazabicyclo- [4.3.0] nonane. Melting point: 270-278 ° C (with decomposition)
• Example 3 Example 3
• Example 2 Analogously to Example 1, the title compound is obtained in the reaction with 2-methylamino-8-azabicyclo- [4.3.0] non-3-ene. Melting point: 260-273 ° C
• Example 4 Analogously to Example 4, the title compound is obtained in the reaction with 2-amino-5-methyl-8-azabicyclo [4.3.0] non-3-ene. Melting point: 240-250 ° C
• Example 7 Analogously to Example 1, the title compound is obtained in the reaction with 2-hydroxymethyl-8-azabicyclo [4.3.0] non-3-ene. Melting point: 290-293 ° C Example 7
• Example 2 Analogously to Example 1, the title compound is obtained in the reaction with 2-methylaminomethyl-8-azabicyclo [4.3.0] non-3-ene. Melting point: 215-218 ° C
• Example 4 Analogously to Example 4, the title compound is obtained in the reaction with 2-amino-5-isopropyl-8-azabicyclo [4.3.0] non-4-ene. Melting point: 265 ° C (with decomposition)
• Example 10 Analogously to Example 10, the title compound is obtained in the reaction with (IS, 6S) -2,8-diazabicyclo- [4.3.0] nonane. Melting point: 242-244 ° C (with decomposition)
• Example 13 Analogously to Example 10, the title compound is obtained in the reaction with 2-methylamino-8-azabicyclo [4.3.0] non-3-ene. Melting point:> 300 ° C Example 13
• Example 10 Analogously to Example 10, the title compound is obtained in the reaction with 2-amino-5-methyl-8-azabicyclo [4.3.0] non-3-ene. Melting point: 148-152 ° C (with decomposition)
• Example 14 Analogously to Example 14, the title compound is obtained in the reaction with 2-hydroxymethyl-8-azabicyclo [4.3.0] non-3-ene. Melting point: 220-221 ° C
• Example 17 Analogously to Example 14, the title compound is obtained in the reaction with 2-methylaminomethyl-8-azabicyclo [4.3.0] non-3-ene. Melting point: 270-273 ° C (with decomposition)
• Example 17

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=6527154

Family Applications (1)

Country Status (15)

Families Citing this family (2)

Family Cites Families (4)

• 1994
  • 1994-09-01 DE DE4431122A patent/DE4431122A1/de not_active Withdrawn
• 1995
  • 1995-08-01 TW TW084107957A patent/TW321650B/zh active
  • 1995-08-21 AU AU33868/95A patent/AU685671B2/en not_active Ceased
  • 1995-08-21 CA CA002198616A patent/CA2198616A1/en not_active Abandoned
  • 1995-08-21 NZ NZ292157A patent/NZ292157A/en unknown
  • 1995-08-21 EP EP95930507A patent/EP0804442A1/de not_active Ceased
  • 1995-08-21 FI FI970827A patent/FI970827A7/fi unknown
  • 1995-08-21 BR BR9508669A patent/BR9508669A/pt not_active Application Discontinuation
  • 1995-08-21 WO PCT/EP1995/003315 patent/WO1996006848A1/de not_active Application Discontinuation
  • 1995-08-21 JP JP8508461A patent/JPH10505345A/ja active Pending
  • 1995-08-21 US US08/793,795 patent/US5744478A/en not_active Expired - Fee Related
  • 1995-08-21 CN CN95194900A patent/CN1156994A/zh active Pending
  • 1995-08-21 HU HU9701252A patent/HUT76797A/hu unknown
  • 1995-08-29 IL IL115095A patent/IL115095A/en not_active IP Right Cessation
  • 1995-08-31 ZA ZA957309A patent/ZA957309B/xx unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events